rapid
growth
global
hivaid
epidem
make
high
prioriti
develop
effect
vaccin
sinc
live
attenu
inactiv
hiv
vaccin
like
approv
clinic
applic
due
safeti
concern
hiv
viru
like
particl
vlp
offer
attract
altern
consid
safer
sinc
lack
viral
genom
got
stabl
eukaryot
cell
line
resist
select
engin
express
structur
protein
gag
env
effici
stabli
confirm
presenc
gag
env
protein
cell
cultur
supernat
could
selfassembl
vlp
vlp
found
abl
elicit
specif
humor
cellular
immun
respons
immun
without
adjuv
cotransfect
stabl
cell
line
viruslik
particl
vlp
vaccin
zhang
x
z
wang
x
zhao
h
et
al
design
immunogen
assess
viruslik
particl
candid
vaccin
sci
china
life
develop
effect
safe
afford
vaccin
human
immunodefici
virusacquir
immun
defici
syndrom
hivaid
need
control
worldwid
hiv
pandem
present
vaccin
hiv
approv
clinic
use
three
obstacl
hinder
creation
vaccin
viral
divers
immun
system
evas
lack
appropri
anim
model
vaccin
evalu
major
approach
use
overcom
viral
immun
evas
exploit
conserv
region
protein
exampl
conserv
site
envelop
glycoprotein
critic
bind
well
coreceptor
envelop
transmembran
protein
coreceptor
bind
site
induc
product
broadli
reactiv
mab
could
potenti
counteract
divers
two
potenti
solut
vaccin
develop
could
potenti
realiz
exploit
prophylact
viruslik
particl
vlp
vaccin
vlp
possess
complex
structur
base
viral
gag
protein
selfassembl
particular
structur
analog
size
morpholog
immatur
particl
noninfecti
replicationdefici
particl
vlp
much
safer
compar
tradit
vaccin
made
chemic
inactiv
attenu
live
virus
differ
form
vlp
distinct
properti
envelop
vlp
display
fulllength
protein
proper
fold
surfac
close
mimic
nativ
envelop
trimer
structur
immun
system
respond
well
particular
antigen
similar
immatur
virus
vlp
antigen
process
present
antigen
major
histocompat
mhc
class
ii
pathway
well
mhc
class
endogen
pathway
induc
immun
respons
therefor
vlp
effect
induc
humor
cellular
immun
reaction
also
wide
accept
ration
vaccin
design
potenti
block
initi
step
infect
respect
vlpbase
vaccin
promis
type
recombin
protein
vaccin
vlp
consid
one
attract
candid
vaccin
hiv
multipl
vlpbase
vaccin
current
investig
howev
still
gener
desir
enhanc
vlp
immunogen
studi
report
construct
vlp
cotransfect
two
kind
plasmid
cell
obtain
mammalian
cell
line
effici
stabli
express
structur
protein
gag
pol
env
vlp
induc
specif
humor
cellular
immun
respons
immun
without
adjuv
plasmid
purchas
invitrogen
carlsbad
ca
usa
plasmid
dgpei
pcdna
envbc
cell
cell
obtain
lab
plasmid
purifi
use
qiagen
plasmid
giga
kit
qiagen
venlo
netherland
final
product
endotoxin
free
unit
mg
posit
serum
obtain
guangxi
aid
patient
antihumanhrpigg
purchas
jackson
immuno
research
laboratori
inc
west
grove
pa
usa
purchas
invitrogen
recombin
cell
express
structur
protein
gag
env
obtain
cotransfect
plasmid
dgpei
cell
plasmid
dgpei
compos
cmv
promot
kanamycin
resist
gene
prokaryot
cell
high
copi
factor
intron
main
structur
protein
gag
pol
env
common
china
strain
clone
express
vector
gag
fuse
n
termin
pol
describ
plasmid
clone
consist
usa
fda
clinic
trial
safeti
control
briefli
cell
maintain
dulbecco
modifi
minim
essenti
medium
dmem
supplement
fetal
calf
serum
hyclon
laboratori
logan
ut
usa
dgpei
plasmid
cotransfect
cell
use
adher
resist
cell
trypsin
serial
dilut
medium
contain
h
transfect
stabl
cell
line
maintain
standard
growth
medium
mg
ml
cell
harvest
assay
western
blot
week
assess
clonal
posit
supernat
collect
centrifug
r
min
min
pass
filter
vlp
pellet
r
min
h
beckman
rotor
sucros
cushion
twice
assembl
confirm
standard
electron
microscopi
analysi
western
blot
analysi
femal
balbc
mice
group
consist
six
anim
week
age
administ
purifi
vlp
plu
dna
intramuscular
inject
control
mice
treat
endotoxinfre
phosphatebuff
salin
pb
immun
schedul
base
regimen
boost
inocul
administ
week
primari
immun
immun
protocol
perform
two
independ
experi
without
addit
adjuv
blood
sampl
collect
tail
bleed
anim
one
week
last
immun
serum
obtain
standard
method
store
use
vlp
prepar
drop
micel
solut
copper
grid
minut
excess
solut
remov
strip
filter
paper
electron
microscop
oper
kv
use
transmiss
electron
microscopi
tem
spleen
immun
mice
harvest
two
week
fourth
immun
approxim
target
cell
sensit
synthet
peptid
concentr
mmol
l
h
cytotox
measur
standard
lactat
dehydrogenas
ldh
releas
assay
ctl
kit
promega
madison
wi
usa
accord
manufactur
instruct
splenic
antigenspecif
cell
identifi
indirectli
use
cytokin
elispot
measur
induc
product
bd
franklin
lake
nj
usa
briefli
nitrocellulos
bottom
plate
coat
overnight
ml
antibodi
nonspecif
bind
block
h
purifi
splenocyt
dispens
triplic
predetermin
densiti
plate
wash
biotinyl
detect
antibodi
ad
anoth
h
dilut
horseradish
peroxidasestreptavidin
ad
well
incub
h
horseradish
peroxidasestreptavidin
substrat
ad
min
colorimetr
reaction
termin
wash
tap
water
spot
count
dri
plasmid
pcdna
envbc
cotransfect
cell
supernat
collect
h
transfect
incub
blood
final
dilut
h
mixtur
infect
ho
cell
deae
ho
cell
harvest
lyse
test
h
use
luciferas
assay
system
promega
accord
manufactur
instruct
extent
luciferas
express
quantit
dynex
mlx
luminomet
record
rel
light
unit
rlu
inhibitori
neutral
concentr
concentr
requir
neutral
preincub
mixtur
calcul
linear
regress
analysi
anova
ie
oneway
anova
follow
fisher
lsd
employ
use
spss
softwar
p
consid
signific
data
point
present
standard
error
gener
stabl
cell
line
express
gene
interest
optim
ratio
vector
dgpei
determin
ratio
optim
chang
select
media
h
select
posit
coloni
express
gag
pol
env
structur
protein
determin
western
blot
assay
data
shown
test
secret
protein
cell
supernat
collect
sucros
densiti
centrifug
pellet
resuspend
pb
assay
sdspage
western
blot
figur
investig
express
stabil
stabl
cell
line
screen
cell
line
maintain
continu
medium
express
gagpol
env
protein
examin
cell
lysat
one
month
month
transfect
respect
effici
express
target
protein
could
still
detect
cell
line
month
vlp
could
also
detect
cellular
supernat
stabl
cell
line
figur
investig
synthesi
assembl
gagpol
env
protein
collect
supernat
posit
cell
centrifug
r
min
h
sucros
gradient
found
gagpol
env
protein
pass
lower
densiti
fraction
migrat
densiti
layer
western
blot
analysi
indic
protein
could
assembl
vlp
includ
gagpol
env
figur
mw
vlp
larg
analyz
nondenatur
page
matrixassist
laser
desorpt
ionizationtim
flight
malditof
mass
spectrometri
confirm
gag
env
assembl
vlp
appli
transmiss
electron
microscopi
tem
supernat
obtain
ultracentrifug
sucros
gradient
cushion
analysi
show
protein
form
viruslik
particl
nm
diamet
shape
size
similar
natur
viru
figur
sera
specif
evalu
immunoblot
result
present
figur
demonstr
antibodi
induc
respons
vaccin
new
epitop
produc
chang
immunodomin
detect
antibodi
respons
vlp
treatment
higher
obtain
dna
figur
contrast
specif
antibodi
respons
vlp
observ
dna
figur
vlp
process
antigen
present
cell
apc
mhc
class
present
cytotox
lymphocyt
ctl
quantifi
tcell
respons
mice
inject
vlp
dna
use
regimen
one
week
last
inject
cell
measur
vitro
assess
cell
death
target
cell
sensit
restrict
ctl
epitop
ctl
respons
low
dna
group
increas
dosedepend
manner
highest
ctl
respons
observ
figur
indic
ctl
epitop
contain
primarili
nc
domain
gag
analysi
splenic
mononuclear
cell
cytolyt
activ
harvest
immun
mice
mastocytoma
cell
pool
six
puls
epitop
use
target
percent
specif
lysi
determin
h
ldhreleas
assay
natur
infect
hivspecif
cell
ctl
associ
antivir
cytokin
play
key
role
viru
recognit
cell
measur
vitro
determin
splenic
product
respons
brief
restimul
ctl
epitop
measur
elispot
result
indic
respons
vlp
immun
also
lower
indic
need
induc
cellular
immun
respons
mous
figur
plasmid
contain
luciferas
full
genom
except
frameshift
mutat
env
gene
cell
express
constitut
gag
env
follow
cotransfect
plasmid
pcdna
envbc
contain
env
gene
two
protein
could
packag
viru
particl
wherein
particl
also
contain
luciferas
particl
refer
pseudotyp
viru
sinc
replic
infect
cell
infect
level
could
detect
quantifi
luciferas
activ
neutral
level
could
evalu
coincub
blood
sampl
cotransfect
supernat
observ
chang
luciferas
result
show
vlp
could
induc
neutral
antibodi
antibodi
level
increas
immun
dose
increas
antibodi
could
also
counteract
infect
pseudotyp
viru
epitop
neutral
antibodi
resid
mainli
neutral
activ
highest
vlp
sampl
indic
low
luciferas
activ
interestingli
plasmid
dna
could
elicit
lower
level
neutral
activ
vlp
amount
test
also
conceiv
ug
optim
dose
neutral
level
differ
dose
group
tend
similar
dilut
figur
major
advantag
vlp
approach
compar
liveattenu
viru
vlp
express
multipl
viral
epitop
stimul
divers
set
immun
respons
without
mani
deleteri
effect
liveattenu
viru
vlp
potenti
activ
endogen
exogen
antigen
process
pathway
lead
present
viral
peptid
mhc
class
class
ii
molecul
multiepitop
vaccin
like
singl
compon
counterpart
gener
broadbas
immun
respons
capabl
clear
immun
evas
mutant
vlp
may
cost
effici
coinocul
multipl
singl
gene
vaccin
futur
phase
clinic
trial
anoth
advantag
vlp
compar
singl
recombin
protein
vaccin
abil
vlp
bind
enter
cell
express
appropri
receptor
vlp
abl
bind
chemokin
receptor
via
enter
profession
antigen
present
cell
macrophag
dendrit
cell
cell
type
express
infect
viral
protein
process
present
mhc
class
molecul
therefor
promot
present
cell
apc
addit
cellfre
vlp
bound
antibodi
taken
phagocyt
cell
via
fc
receptor
thu
increas
mhc
class
ii
present
vlp
express
baculoviru
express
system
saccharomyc
cerevisia
system
produc
larg
amount
particl
eukaryot
cell
howev
usual
limit
express
one
gene
therefor
easili
use
produc
multigen
vlp
addit
order
particl
bud
yeast
outer
membran
need
remov
overcom
disadvantag
first
cotransfect
two
plasmid
use
neomycin
stabl
screen
marker
screen
mammalian
cell
line
could
express
gagpol
env
protein
high
effici
gag
protein
readili
pack
nonenvelop
vlp
presenc
env
protein
provid
antigen
determin
took
advantag
gag
selfassembl
coexpress
gag
env
produc
vlp
approach
demonstr
cell
line
could
produc
stabl
vlp
also
secret
signific
quantiti
vlp
supernat
vlp
produc
method
without
viral
nucleic
acid
safer
also
induc
strong
humor
cellular
immun
respons
provid
foundat
improv
hiv
vaccin
recombin
gagpol
env
protein
similar
structur
wild
addit
work
requir
fulli
understand
approach
could
use
advanc
clinic
applic
